Search

Your search keyword '"Fraser, G. A. M."' showing total 3 results
Start Over Author "Fraser, G. A. M."
3 results on '"Fraser, G. A. M."'

1. Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials.

Author

Tedeschi, A., Ahn, I. E., Fraser, G. A. M., Greil, R., Munir, T., Kay, N. E., Flinn, I. W., Lee, S., Saifan, C., Kearbey, J., Patel, S., and Barrientos, J. C.

Subjects
CHRONIC lymphocytic leukemia, CLINICAL trials
Abstract

B Introduction I : i b Sustained progression-free survival (PFS) has been demonstrated with continuous Ibr-based therapy and with time-limited treatment (tx) with the Ibr + venetoclax (Ven) combination in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). No patient with a dose reduction had recurrence of the same cardiac AE at the same or worse severity, both overall and as a serious AE (vs 22% and 11% in patients without dose reduction, respectively). In total, 17/212 (8%) patients had dose reductions of Ibr (to 280 mg, I n i = 8; to 140 mg, I n i = 9); only 4 patients had a dose reduction specifically following a cardiac AE. [Extracted from the article]

Published
2023
Full Text
View/download PDF

2. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Author

Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M., Stilgenbauer, S., Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M., and Stilgenbauer, S.

Abstract

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR) was 40.4% (42/104). ORRs were similar irrespective of TP53 mutation (36.1% (13/36) vs 43.3% (26/60) for patients with vs without mutation) or IGHV mutation status (45.0% (9/20) vs 39.1% (27/68)); however, patients with del(17p) had lower ORRs than those without del(17p) (21.7% (5/22) vs 47.1% (33/70); P = 0.049). No significant differences in progression-free survival and overall survival (OS) were observed when comparing subgroups defined by the presence or absence of high-risk genetic characteristics. In multivariate analyses, only multiple prior therapies (>= 3 lines) significantly impacted outcomes (median OS: 21.2 months vs not reached; P = 0.019). This analysis indicates that lenalidomide is active in patients with relapsed/refractory CLL with unfavorable genetic profiles, including TP53 inactivation or unmutated IGHV.

Published
2016

3. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Author

Bühler, A, primary, Wendtner, C-M, additional, Kipps, T J, additional, Rassenti, L, additional, Fraser, G A M, additional, Michallet, A-S, additional, Hillmen, P, additional, Dürig, J, additional, Gregory, S A, additional, Kalaycio, M, additional, Aurran-Schleinitz, T, additional, Trentin, L, additional, Gribben, J G, additional, Chanan-Khan, A, additional, Purse, B, additional, Zhang, J, additional, De Bedout, S, additional, Mei, J, additional, Hallek, M, additional, and Stilgenbauer, S, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results